Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.36 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809363 | 0.95 | GRK6 (0.42) | GRK6CNR2KDM4EALDH1A1KCNH2 | |
| SCHEMBL2810268 | 0.87 | CLPP (0.42) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2813934 | 0.87 | CLPP (0.42) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2812343 | 0.85 | CLPP (0.45) | KDM4EALDH1A1POLBMAPTHPGD | |
| SCHEMBL2812821 | 0.85 | SMN1; SMN2 (0.42) | KDM4EALDH1A1POLBMAPTHPGD | |
| SCHEMBL2813867 | 0.84 | CLPP (0.40) | GRK6MAPTTSHRCCR3 | |
| SCHEMBL2814373 | 0.83 | PIK3CA (0.45) | KDM4EALDH1A1POLBMAPTHPGD | |
| SCHEMBL2809612 | 0.81 | CXCR4 (0.41) | KDM4EALDH1A1POLBMAPTHPGD | |
| SCHEMBL538311 | 0.81 | ALDH1A1 (0.42) | KDM4EALDH1A1POLBHPGDTSHR | |
| SCHEMBL14405862 | 0.81 | TLR9 (0.41) | ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414359-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | GRK6 2330/4885CNR2 1666/4885KDM4E 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.